Navigation Links
Skewered pumpkins

This release is available in German.

We encounter valves every day, whether in the water faucet, the carburetor in our car, or our bicycle tire tube. Valves are also present in the world of nanotechnology. A team of researchers headed by J. Fraser Stoddart and Jeffrey I. Zink at the University of California, Los Angeles, has now developed a new nanovalve. In the journal Angewandte Chemie, the scientists reveal what is special about it: In contrast to prior versions, which only function in organic solvents, this valve operates in an aqueous environment and under physiological conditionsprerequisites for any application as a gate for nanoscopic drug-transport agents, which need to set their cargo free at the right place and time.

In order for pharmaceuticals to affect only the target diseased organ, suitable nanopackaging is required to bring the drug to the target area and release it only there. One example of a good nanoscopic packaging agent is a tiny sphere of porous silica. Its pores can be filled with the drug and closed with tiny controllable valves.

The scientists attached stem-shaped molecules onto the surface of the porous spheres and filled the pores with guest molecules. At neutral to acidic pH values, they stacked cucurbituril molecules onto these stems. Cucurbituril is a fat, ring-shaped molecule reminiscent of a pumpkin that has both ends hollowed out. The resulting supramolecular structure, which resembles a skewered pumpkin and is known to chemists as a pseudorotaxane, blocks the pores, so that the guest molecules cannot exit. The nanovalve is closed.

If the pH value is raised into the basic range, however, the interaction between the pumpkins and the skewers is weakened, and the pumpkins come off, opening the pores. Now the valves are open and the guest molecules can exit.

At this point the molecular details of the individual components still need to be tweaked. The goal: very small differences in pH values between healthy and diseased tissue should be sufficient to switch the valves and release the drug only in diseased cells.


Contact: Jeffrey I. Zink

Post Your Comments:
Related Image:
Skewered pumpkins
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: